CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

NCT00087789 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

GENETIC: CERE-110: Adeno-Associated Virus Delivery of NGF

Sponsor

Sangamo Therapeutics

Collaborators

[object Object]